NCT02945657View on ClinicalTrials.gov

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

June 8, 2017

Study Completion Date

June 8, 2017

Conditions
Atopic Dermatitis
Interventions
DRUG

MM36 topical ointment, 1%

Twice daily application for 28 consecutive days

Trial Locations (12)

23502

Medimetriks Investigational Site, Norfolk

33125

Medimetriks Investigational Site, Miami

64506

Medimetriks Investigational Site, Saint Joseph

77030

Medimetriks Investigational Site, Houston

78759

Medimetriks Investigational Site, Austin

92123

Medimetriks Investigational Site, San Diego

92697

Medimetriks Investigational Site, Irvine

94538

Medimetriks Investigational Site, Fremont

97239

Medimetriks Investigational Site, Portland

99202

Medimetriks Investigational Site, Spokane

Unknown

Medimetriks Investigational Site, San Pedro Sula

Medimetriks Investigational Site, Panama City

Sponsors
All Listed Sponsors
lead

Medimetriks Pharmaceuticals, Inc

INDUSTRY

NCT02945657 - Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis | Biotech Hunter | Biotech Hunter